EMA approves Mounjaro’s use for children as young as ten for diabetes management

In a significant development for pediatric diabetes treatment, the European Medicines Agency (EMA) has approved the use of Mounjaro for children as young as ten years old with type 2 diabetes. The decision expands treatment options for younger patients dealing with this complex condition, which is often linked to obesity and can lead to serious complications such as heart disease, kidney failure, and stroke.

A New Option for Pediatric Diabetes Care

Previously, treatment options for children with type 2 diabetes were largely limited to metformin and insulin. Mounjaro, which contains the active ingredient tirzepatide, offers a new alternative when combined with a reduced-calorie diet and increased physical activity. The drug is known for its effectiveness in controlling blood sugar and promoting weight loss, and it is already approved for adults in Europe for both type 2 diabetes and obesity management.

In a late-stage clinical trial published in The Lancet, researchers studied the effects of Mounjaro in children between the ages of 10 and 17. Over a 52-week period, participants experienced significant improvements in blood sugar control and a meaningful reduction in body weight. By the 30-week mark, children receiving the 10mg dose achieved an average body mass index (BMI) reduction of 11.2%.

sbb-itb-e2779c3

Promising Results but Some Side Effects

While the trial showed promising outcomes, some children experienced side effects similar to those reported in adults. These included diarrhea, nausea, vomiting, and abdominal pain. However, researchers noted that very few participants discontinued the treatment due to these effects.

Dr. Tamara Hannon, director of the Clinical Diabetes Program at Indiana University School of Medicine and lead author of the study, underscored the significance of the findings. "Youth living with type 2 diabetes often face a more aggressive disease course – and in many instances, first-line treatments like metformin and insulin fail to control their [blood sugar] adequately", she said. "These results offer a promising opportunity to help shift the long-term health trajectory for young people living with this complex condition."

Addressing a Growing Health Crisis

The EMA’s recommendation comes amid rising concerns over childhood obesity and its health consequences. According to the latest NHS data analyzed by the Royal Society for Public Health, more than a third of primary school children in England are overweight or obese. Among children in Year 6 (ages 10 to 11), over 22% are classified as clinically obese. Obesity significantly increases the risk of developing chronic conditions, including type 2 diabetes, heart disease, and certain cancers, both in childhood and later in life.

Type 2 diabetes, which accounts for 90% of diabetes cases in the UK, occurs when the body becomes resistant to insulin or struggles to produce enough of it. Persistently high blood sugar levels can result in long-term damage to organs such as the heart, kidneys, and eyes. Symptoms of the condition include excessive thirst, frequent urination, and fatigue, although some individuals may show no obvious signs.

How Mounjaro Works

Mounjaro is part of a class of drugs known as GLP-1 agonists, which mimic a naturally occurring hormone in the gut. This hormone assists the body in releasing insulin, balancing blood sugar levels, reducing appetite, and slowing digestion. For adults, Mounjaro has been shown to lead to significant weight loss, with some losing up to 20% of their body weight in just over a year.

Previously, Novo Nordisk’s weight-loss drug Wegovy was approved in Europe for use in children aged 12 and older. The EMA’s decision to lower the age limit for Mounjaro to 10 years old marks another milestone in addressing type 2 diabetes in young populations.

Conclusion

With the EMA’s approval, Mounjaro offers a new hope for children facing the challenges of type 2 diabetes. By improving blood sugar control and supporting weight loss, the drug has the potential to shift the course of a condition that affects millions and is becoming increasingly common in younger age groups. As childhood obesity rates remain a pressing concern, treatments like Mounjaro could play a key role in improving long-term health outcomes for the next generation.

Read the source